0001104659-22-072381.txt : 20220617
0001104659-22-072381.hdr.sgml : 20220617
20220617160607
ACCESSION NUMBER: 0001104659-22-072381
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220614
FILED AS OF DATE: 20220617
DATE AS OF CHANGE: 20220617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferguson Kenneth M.
CENTRAL INDEX KEY: 0001934344
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50626
FILM NUMBER: 221023791
MAIL ADDRESS:
STREET 1: 2125 1ST AVENUE #2902
CITY: SEATTLE
STATE: WA
ZIP: 98121-2121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001130166
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911766850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 908-517-7330
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER COMPANY:
FORMER CONFORMED NAME: XCYTE THERAPIES INC
DATE OF NAME CHANGE: 20001218
4/A
1
tm2218810-1_4a.xml
FORM 4/A
X0306
4/A
2022-06-14
2022-06-16
0
0001130166
Cyclacel Pharmaceuticals, Inc.
CYCC
0001934344
Ferguson Kenneth M.
C/O CYCLACEL PHARMACEUTICALS, INC.,
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS
NJ
07922
1
0
0
0
Common Stock
2022-06-14
4
A
0
23733
0
A
23733
D
Stock Option (right to buy)
1.11
2022-06-14
4
A
0
47467
0
A
2023-06-14
2032-06-14
Common Stock
47467
47467
D
The Reporting Person received an award of 23,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025.
This Form 4 is being amended to correct a typographical error in the number of restricted stock units granted to the Reporting Person on June 14, 2022. 23,733 shares of restricted stock units were granted to the Reporting Person.
The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.
These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
/s/ Kenneth M. Ferguson
2022-06-17